Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    P40 - Multimodality of Advanced Lung Cancer - Clinical Outcomes

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Multimodality of Advanced Lung Cancer
    • +

      P40.01 - Maintenance Anlotinib After Induction Therapy With Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Phase 2 Study

      00:00 - 00:00  |  Presenter: Yongqian Shu

      • Abstract

      Loading...

    • +

      P40.02 - Pemetrexed in Advanced-stage Lymphoepithelioma Carcinoma of Lung

      00:00 - 00:00  |  Presenter: Ri-Qiang Liao

      • Abstract

      Loading...

    • +

      P40.03 - Palliative Radiotherapy Decreased Circulating White Blood Cells in Patients With Stage IV Lung Cancer

      00:00 - 00:00  |  Presenter: Feng Ming Spring Kong

      • Abstract

      Loading...

    • +

      P40.04 - CNS Adverse Events and Survival in Patients with NSCLC Brain Metastases Treated With Concurrent Radiation and Immunotherapy

      00:00 - 00:00  |  Presenter: David Riley

      • Abstract

      Loading...

    • +

      P40.05 - Radiation-Related Platelet Reduction in Patients With Stage IV Lung Cancer

      00:00 - 00:00  |  Presenter: Feng Ming Spring Kong

      • Abstract

      Loading...

    • +

      P40.06 - A Real-World Study: Efficacy and Safety of Anlotinib for Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Qian Chu

      • Abstract

      Loading...

    • +

      P40.07 - Immunotherapy Toxicity in Lung Cancer & the Impact of Thoracic Radiation Therapy

      00:00 - 00:00  |  Presenter: Ciani Ellison

      • Abstract

      Loading...

    • +

      P40.08 - Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors

      00:00 - 00:00  |  Presenter: Sara Manglaviti

      • Abstract

      Loading...

    • +

      P40.09 - Using Real World Data to Identify a Patient Cohort Who Require Prehabilitation to Improve Treatment Rates for Stage 3 NSCLC

      00:00 - 00:00  |  Presenter: Benjamin W. A. Langley

      • Abstract

      Loading...

    • +

      P40.10 - Brain Metastases in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy. Real World Data From a Tertiary Hospital in Spain

      00:00 - 00:00  |  Presenter: Yago Garitaonaindia

      • Abstract

      Loading...

    • +

      P40.11 - Trimodality Therapy Protocol in 144 Superior Sulcus Patients: Good Results Even for Extended Resections and Indications

      00:00 - 00:00  |  Presenter: Marinus Anne Paul

      • Abstract

      Loading...

    • +

      P40.12 - Cardiotoxicity in Lung Cancer Patients Treated With Immune-Checkpoints Inhibitors

      00:00 - 00:00  |  Presenter: Mariola Blanco Clemente

      • Abstract

      Loading...

    • +

      P40.13 - Lung Cancer 5-Year Survival in Croatia - Our Experience

      00:00 - 00:00  |  Presenter: Marko Jakopović

      • Abstract

      Loading...

    • +

      P40.14 - Efficacy and Safety of Endostar Combined With Camrelizumab and Chemotherapy in Treatment of Advanced NSCLC: A Multi-Center Retrospective Study

      00:00 - 00:00  |  Presenter: Lin Wu

      • Abstract

      Loading...

    • +

      P40.15 - Proton Pump Inhibitors, Prior Therapy and Survival in Patients Treated With Immune Checkpoint Inhibitors for Advanced NSCLC

      00:00 - 00:00  |  Presenter: Marium Husain

      • Abstract

      Loading...

    • +

      P40.16 - Real-World Data and Racial Outcomes for NSCLC in The Chemo-Immunotherapy Era

      00:00 - 00:00  |  Presenter: Danny Markabawi

      • Abstract

      Loading...

    • +

      P40.17 - Palliative Radiotherapy Decreased K+ and Ca2+of the Blood in Patients With Stage IV Lung Cancer

      00:00 - 00:00  |  Presenter: Feng Ming Spring Kong

      • Abstract

      Loading...

    • +

      P40.18 - Second Line Immunotherapy After Progression on a Different First Line Immunotherapy in Advanced Non-Small Cell Lung Cancer With Focus On Elderly

      00:00 - 00:00  |  Presenter: Karan Seegobin

      • Abstract

      Loading...

    • +

      P40.19 - Efficacy and Toxicity of Third-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Sara Manglaviti

      • Abstract

      Loading...

    • +

      P40.20 - Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients With Metastatic Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Sabin Goktas Aydin

      • Abstract

      Loading...

  • +

    P41 - Multimodality of Advanced Lung Cancer - Clinical Trials, Case Report

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Multimodality of Advanced Lung Cancer
    • +

      P41.01 - Abscopal Response Induced by Thermal Ablation in Advanced NSCLC Patients Failed From Immunotherapy: Preliminary Result From a Phase 2 Trial

      00:00 - 00:00  |  Presenter: Chuchu Shao

      • Abstract

      Loading...

    • +

      P41.02 - Surgery for Small Pulmonary NUT Carcinoma: Case Report

      00:00 - 00:00  |  Presenter: YUICHI SAITO

      • Abstract

      Loading...

  • +

    P42 - Multimodality of Advanced Lung Cancer - Prognostic Factors

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Multimodality of Advanced Lung Cancer
    • +

      P42.01 - Tumor Size is an Independent Prognostic Factor after Pulmonary Metastasectomy

      00:00 - 00:00  |  Presenter: Simona Sobrero

      • Abstract

      Loading...

    • +

      P42.02 - Prognostic Indicators for Conventional Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients in Resource-Limited Country

      00:00 - 00:00  |  Presenter: Chawalit Chayangsu

      • Abstract

      Loading...

    • +

      P42.03 - Predictive Factors of Response to PD-(L)1 Inhibitors in Patients With Advanced Non-Small Cell Lung and High PD-L1 Expression

      00:00 - 00:00  |  Presenter: Andrés Barba Joaquín

      • Abstract

      Loading...

    • +

      P42.04 - Prognosis Factors in Advanced Lung Cancer Patients Treated With Checkpoint Inhibitor-Based Immunotherapy

      00:00 - 00:00  |  Presenter: Kan Wu

      • Abstract

      Loading...

  • +

    P43 - Multimodality of Advanced Lung Cancer - Others

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Multimodality of Advanced Lung Cancer
    • +

      P43.01 - Three-Dimensional Virtual Planning for Nodule Resection in Solid Organs: A Systematic Review and Meta-Analysis

      00:00 - 00:00  |  Presenter: Paulo Alfredo Casanova Schulze

      • Abstract

      Loading...

    • +

      P43.02 - Inconsistencies Within Biomarker Test Reports Provide Opportunities for Future Patient Education

      00:00 - 00:00  |  Presenter: Nikki Martin

      • Abstract

      Loading...

    • +

      P43.03 - LUPA-01: An Observational Study to Monitor Lung Cancer Patients’ Activity and Assess Performance Status through a Wearable Device in Spain

      00:00 - 00:00  |  Presenter: Santiago Ponce Aix

      • Abstract

      Loading...

  • +

    P44 - Nursing and Allied Health Professionals

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Nursing and Allied Health Professionals
    • +

      P44.01 - Clinical Predictive Markers of Response to Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC).

      00:00 - 00:00  |  Presenter: Raena Denise Rhone

      • Abstract

      Loading...

    • +

      P44.02 - Prevalence, Onset, and Severity of Renal Impairment With Pemetrexed/Carboplatin +/- Pembrolizumab in Metastatic Non-Squamous NSCLC

      00:00 - 00:00  |  Presenter: Jennifer Z Miller

      • Abstract

      Loading...

  • +

    P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P45.01 - Therapeutic effectiveness of Lorlatinib After Alectinib in Japanese Patients With ALK-Positive NSCLC in Real-World

      00:00 - 00:00  |  Presenter: Yasushi Goto

      • Abstract

      Loading...

    • +

      P45.02 - Molecular Profile of Resistance Mutations Post Multiple Lines of Tyrosine Kinase Inhibitors in ALK-Positive Non-Small-Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Moushumi Suryavanshi

      • Abstract

      Loading...

    • +

      P45.03 - Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy

      00:00 - 00:00  |  Presenter: Enriqueta Felip

      • Abstract

      Loading...

    • +

      P45.04 - Phase II Study of Brigatinib in ROS1 Positive Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Crizotinib: Barossa Cohort 2

      00:00 - 00:00  |  Presenter: Jun Sakakibara-Konishi

      • Abstract

      Loading...

    • +

      P45.05 - Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival

      00:00 - 00:00  |  Presenter: Sally CM Lau

      • Abstract

      Loading...

    • +

      P45.06 - Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Yi-Long Wu

      • Abstract

      Loading...

    • +

      P45.07 - Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC

      00:00 - 00:00  |  Presenter: Sabine Schmid

      • Abstract

      Loading...

    • +

      P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

      00:00 - 00:00  |  Presenter: Shun Lu

      • Abstract

      Loading...

    • +

      P45.09 - Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada

      00:00 - 00:00  |  Presenter: Simren Chotai

      • Abstract

      Loading...

    • +

      P45.10 - Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis

      00:00 - 00:00  |  Presenter: Michela Febbraro

      • Abstract

      Loading...

    • +

      P45.11 - Co-occurring CDKN2A/B Alteration Is Associated With Worse Survival Outcomes in Advanced ALK-Positive Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Oscar Arrieta

      • Abstract

      Loading...

    • +

      P45.12 - Renal Function Change During Alectinib in ALK Rearranged Non-Small Cell Lung Cancer: A Retrospective Multicentre Analysis

      00:00 - 00:00  |  Presenter: Chiara Paratore

      • Abstract

      Loading...

    • +

      P45.13 - Efficacy and Safety of Crizotinib in Real-World ROS1-rearranged NSCLC: A Retrospective Canadian Cohort

      00:00 - 00:00

      • Abstract

      Loading...

    • +

      P45.14 - Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Alterated Non-Small-Cell Lung Cancer Patients in China

      00:00 - 00:00  |  Presenter: Shaoyu Yang

      • Abstract

      Loading...

    • +

      P45.15 - Clinical Outcomes, Long-Term Survival and Toleration With Sequential Therapy of First-Line Crizotinib Followed by Alectinib in ALK+ NSCLC

      00:00 - 00:00  |  Presenter: Zihua Zou

      • Abstract

      Loading...

    • +

      P45.16 - Adverse Event Burden of Oral Tyrosine Kinase Inhibitors in EGFR and ALK Metastatic Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: David Riley

      • Abstract

      Loading...

    • +

      P45.17 - Outcomes of Patients on ALK Inhibitor Therapy in NHS Tayside Scotland UK

      00:00 - 00:00  |  Presenter: Sherie George

      • Abstract

      Loading...

    • +

      P45.18 - NSCLC Patients With ALK Gene Rearrangement – Croatian Experience

      00:00 - 00:00  |  Presenter: Marko Jakopović

      • Abstract

      Loading...

  • +

    P46 - Novel Therapeutics and Targeted Therapies - Case Report

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P46.01 - Progression After Targeted-therapy – An EGFR Case Report

      00:00 - 00:00  |  Presenter: Francisco Neri

      • Abstract

      Loading...

    • +

      P46.02 - Impact of Real-World DNA- and RNA-Based Rebiopsy Testing in EGFR-Mutated NSCLC Progressing on Osimertinib.

      00:00 - 00:00  |  Presenter: Edyta Maria Urbanska

      • Abstract

      Loading...

    • +

      P46.03 - Targeting ROS1 Gene Rearrangement by Crizotinib as Neoadjuvant Treatment Before Definitive Radiotherapy in Locally Advanced NSCLC

      00:00 - 00:00  |  Presenter: Jens Benn Sørensen

      • Abstract

      Loading...

    • +

      P46.04 - Different Effects of Crizotinib Treatment in Three Lung Adenocarcinoma Patients With Various ROS1 Fusion Variants

      00:00 - 00:00  |  Presenter: Yuta Ohishi

      • Abstract

      Loading...

    • +

      P46.05 - Durable Response to Double Dose Osimertinib 160mg in EGFR-Mutated Non-Small Cell Lung Cancer With Brain Metastases

      00:00 - 00:00  |  Presenter: Myungwoo Nam

      • Abstract

      Loading...

    • +

      P46.06 - Response of an Advanced Lung Cancer Mass to Targeted Therapy

      00:00 - 00:00  |  Presenter: Paulo Alfredo Casanova Schulze

      • Abstract

      Loading...

    • +

      P46.07 - Afatinib-Related Pneumonitis in Metastatic EGFR-Positive NSCLC

      00:00 - 00:00  |  Presenter: Sita Andarini

      • Abstract

      Loading...

  • +

    P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P47.01 - SGNTUC-019: Phase 2 Study of Tucatinib and Trastuzumab in Solid Tumors: Lung Cancer Cohorts (Clinical Trial in Progress)

      00:00 - 00:00  |  Presenter: Martin Reck

      • Abstract

      Loading...

    • +

      P47.02 - EV-202: Phase 2 Study of Enfortumab Vedotin for Previously Treated Advanced Solid Tumors Including Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Seema Gorla

      • Abstract

      Loading...

    • +

      P47.03 - Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2

      00:00 - 00:00  |  Presenter: Jonathan Goldman

      • Abstract

      Loading...

    • +

      P47.04 - TROPION-Lung02: Datopotamab Deruxtecan (Dato-DXd) Plus Pembrolizumab and Platinum-Based Chemotherapy in Advanced NSCLC

      00:00 - 00:00  |  Presenter: Benjamin Levy

      • Abstract

      Loading...

    • +

      P47.05 - A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)

      00:00 - 00:00  |  Presenter: Melissa L Johnson

      • Abstract

      Loading...

    • +

      P47.06 - TROPION-Lung04: Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab and Platinum-Based Chemotherapy in Advanced NSCLC

      00:00 - 00:00  |  Presenter: Hossein Borghaei

      • Abstract

      Loading...

    • +

      P47.07 - KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC

      00:00 - 00:00  |  Presenter: David R. Spigel

      • Abstract

      Loading...

    • +

      P47.08 - A Phase II, Single-arm, Multicenter, Efficacy of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

      00:00 - 00:00  |  Presenter: Sehhoon Park

      • Abstract

      Loading...

    • +

      P47.09 - Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2

      00:00 - 00:00  |  Presenter: Christophe Dooms

      • Abstract

      Loading...

    • +

      P47.10 - Neoadjuvant Osimertinib in EGFR-Mutant Stage IIIA/B NSCLC - A Phase 2 Open-Label Pilot Study

      00:00 - 00:00  |  Presenter: Waleed Kian

      • Abstract

      Loading...

    • +

      P47.11 - COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib

      00:00 - 00:00  |  Presenter: Lecia V. Sequist

      • Abstract

      Loading...

    • +

      P47.12 - ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib With Crizotinib After Disease Progression

      00:00 - 00:00  |  Presenter: Malinda Itchins

      • Abstract

      Loading...

    • +

      P47.13 - First-in-Human, Dose Escalation and Expansion Study of MT-6402 in Patients With PD-L1 Expressing Advanced Solid Tumors

      00:00 - 00:00  |  Presenter: David R. Spigel

      • Abstract

      Loading...

    • +

      P47.14 - Study Design of SCORPION: Multi-Center, Phase II Study Following Platinum-Based Chemotherapy Plus ICIs in Patients with NSCLC

      00:00 - 00:00  |  Presenter: Reiko Matsuzawa

      • Abstract

      Loading...

    • +

      P47.15 - A Phase IA Study of Ceritinib + Trametinib in Patients With Advanced ALK- or ROS1- Rearranged NSCLC: Preliminary Results

      00:00 - 00:00  |  Presenter: Matthew Lara

      • Abstract

      Loading...

    • +

      P47.16 - Preliminary Efficacy and Safety Results About a Phase II Trial of Afatinib and Bevacizumab in Untreated NSCLC Harboring EGFR Sensitive Mutations

      00:00 - 00:00  |  Presenter: Yu Feng

      • Abstract

      Loading...

    • +

      P47.17 - Capmatinib vs Docetaxel in Pretreated Patients With MET Exon 14 Skipping–mutated Stage IIIB/IIIC or IV NSCLC (GeoMETry-III)

      00:00 - 00:00  |  Presenter: Pierre-Jean Souquet

      • Abstract

      Loading...

    • +

      P47.18 - Almonertinib With Radiotherapy vs Concurrent Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC (ADVANCE Trial)

      00:00 - 00:00  |  Presenter: Nan Bi

      • Abstract

      Loading...

  • +

    P48 - Novel Therapeutics and Targeted Therapies - EGFR

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P48.01 - Anlotinib Plus Docetaxel vs Docetaxel for 2nd-Line Treatment of EGFR negative NSCLC (ALTER-L018): A Randomized Phase II Trial

      00:00 - 00:00  |  Presenter: Lin Wu

      • Abstract

      Loading...

    • +

      P48.02 - Real-World Data of Dacomitinib in EGFR TKI-Naïve Patients With Advanced Epidermal Growth Factor Receptor-positive Non-small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Jinyao Zhang

      • Abstract

      Loading...

    • +

      P48.03 - Spectrum of Resistance Mechanisms to First, Second and Third Generation Tyrosine Kinase Inhibitors in EGFR Mutant NSCLC Patients

      00:00 - 00:00  |  Presenter: Moushumi Suryavanshi

      • Abstract

      Loading...

    • +

      P48.04 - EGFR Germline Mutations in Chinese Lung Cancer Patients: A Single Institutional, Retrospective Study

      00:00 - 00:00  |  Presenter: Chengzhi Zhou

      • Abstract

      Loading...

    • +

      P48.05 - Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?

      00:00 - 00:00  |  Presenter: Miguel Garcia

      • Abstract

      Loading...

    • +

      P48.06 - A Network Meta-Analysis (MA) of First-Line Lung Cancer Treatment With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)

      00:00 - 00:00  |  Presenter: Yvonne Ang

      • Abstract

      Loading...

    • +

      P48.07 - Real-World Impact of Upfront Osimertinib in Reducing Health Resource Utilization by Preventing Brain Metastases

      00:00 - 00:00  |  Presenter: Francesca Simionato

      • Abstract

      Loading...

    • +

      P48.08 - The Efficacy and Clinical Survival Outcome of Different First-Line Treatments in EGFR Mutant Non-Small Cell Lung Cancer With Brain Metastases

      00:00 - 00:00  |  Presenter: Huijuan wang

      • Abstract

      Loading...

    • +

      P48.09 - Body Mass Index Predicts Benefit From Adding Metformin to EGFR-TKIs in Patients With Lung Adenocarcinoma: Subanalysis From an RCT

      00:00 - 00:00  |  Presenter: Oscar Arrieta

      • Abstract

      Loading...

    • +

      P48.10 - Efficacy of EGFR-TKIs vs TKIs Plus Chemotherapy as First-Line Treatment in EGFR-Mutation Lung Adenocarcinoma With Liver Metastases

      00:00 - 00:00  |  Presenter: Huijuan wang

      • Abstract

      Loading...

    • +

      P48.11 - ctDNA Dynamic Detection Reveals the Advantages of EGFR Tyrosine Kinase Inhibitors Combined With Chemotherapy in NSCLC Patients

      00:00 - 00:00  |  Presenter: Weineng Feng

      • Abstract

      Loading...

    • +

      P48.12 - Concurrent Chemotherapy and First-Generation EGFR-TKI as First-Line Treatment in Advanced Lung Adenocarcinoma Harboring EGFR Mutation

      00:00 - 00:00  |  Presenter: Ziyi Xu

      • Abstract

      Loading...

    • +

      P48.13 - Clinical Factors Associated With Treatment Outcomes in EGFR Mutant Non-Small Cell Lung Cancer Patients. Real Life Experience in Argentina

      00:00 - 00:00  |  Presenter: luis Roberto basbus

      • Abstract

      Loading...

    • +

      P48.14 - Metastatic NSCLC -Re-Challenging With Fist Generation TKI After a Drug Free Holiday After Resistance to 3rd Generation TKI

      00:00 - 00:00  |  Presenter: Suryakanta Acharya

      • Abstract

      Loading...

    • +

      P48.15 - EGFR Mutated Non-Small Cell Lung Cancer Treatment Pathway – What Is the Best Way?

      00:00 - 00:00  |  Presenter: Marta Soares

      • Abstract

      Loading...

    • +

      P48.16 - The Effect and Safety of Anlotinib as a Third Line or Further Therapy in Non-Small Cell Lung Cancer Patients With Liver Metastasis

      00:00 - 00:00  |  Presenter: Yinchen Shen

      • Abstract

      Loading...

    • +

      P48.17 - Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib

      00:00 - 00:00  |  Presenter: Jorge Nieva

      • Abstract

      Loading...

  • +

    P49 - Novel Therapeutics and Targeted Therapies - EGFR Major

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P49.01 - Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC

      00:00 - 00:00  |  Presenter: Song Dong

      • Abstract

      Loading...